http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 31 Jul 2026 07:26:03 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Corporate+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Corporate+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Corporate+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/FDA/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/FDA/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/FDA/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/FDA/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Trader+Talk/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Trader+Talk/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Trader+Talk/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Trader+Talk/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Hot+Corp.+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Hot+Corp.+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Hot+Corp.+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Hot+Corp.+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Hot+FDA+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Hot+FDA+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Hot+FDA+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html <p>Novo Nordisk (NYSE: NVO) announced that its experimental drug ziltivekimab did not reduce the risk of major adverse cardiovascular events (MACE) in a phase 3 clinical trial, despite producing the expected biological effects.</p><p>The ZEUS trial, a double-blind, placebo-controlled study enrolling over 6,300 patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and elevated inflammation markers, compared once-monthly ziltivekimab 15 mg against placebo. The primary endpoint was a reduction in MACE, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. The hazard ratio was 0.99 with a 95% confidence interval of 0.88 to 1.11, indicating no meaningful benefit over http://www.streetinsider.com/Hot+FDA+News/Novo+Nordisk%27s+ziltivekimab+fails+to+reduce+heart+risk+in+ZEUS+trial/26846779.html Fri, 31 Jul 2026 07:26:03 -0400 NOVO NVO http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Trading+Halts/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Corporate+News/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html <p>Metsera Inc. (NASDAQ: MTSR) announced that its board determined a revised acquisition proposal from Novo Nordisk A/S (Copenhagen: NOVO B) constitutes a "Superior Company Proposal" under its existing merger agreement with Pfizer.</p><p>The Novo Nordisk proposal values Metsera at up to $86.20 per share, totaling approximately $10.0 billion. The structure includes an immediate payment of $62.20 per share in cash upon signing a definitive agreement, increased from $56.50 in the original proposal. Shareholders would also receive a dividend of $62.20 per share and contingent value rights worth up to $24.00 per share based on development and regulatory milestones.</p><p>This compares to a http://www.streetinsider.com/Mergers+and+Acquisitions/Metsera+declares+Novo+Nordisk%27s+%2410+billion+bid+superior+to+Pfizer+offer/25550355.html Tue, 04 Nov 2025 09:10:08 -0400 B MTSR NOVO NOVOB NVO PFE